Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effects of Erlotinib treatment on GSCs (RNA-seq)

ABSTRACT: Effects of Erlotinib treatment on GSCs (RNA-seq)

PROVIDER: PRJNA946312 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23908425_1.fastq.gz	Fastqsanger.gz
	SRR23908425_2.fastq.gz	Fastqsanger.gz
	SRR23908426_1.fastq.gz	Fastqsanger.gz
	SRR23908426_2.fastq.gz	Fastqsanger.gz
	SRR23908427_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Effects of Erlotinib treatment on GSCs (RNA-seq)

Project description:We investigated the transcriptional regulation by EGFR signaling in GSCs

2023-06-10 | GSE227674 | GEO

Gene expression profiling of Glioma Stem Cells (GSCs) and their differentiated cell counterparts after MG132 treatment

Project description:Analysis of genes in GSCs and differentiated cells that are induced by MG132 treatment. Total RNAs were isolated from GSCs and differentiated cells after MG132 or DMSO treatment for 6 hrs in serum-free media

2014-10-15 | E-GEOD-62356 | biostudies-arrayexpress

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

Project description:The non-small cell lung cancer (NSCLC) cell line HCC827 harbors an activating EGFR mutation (exon 19 deletion) that confers sensitivity to the FDA-approved EGFR inhibitor erlotinib. By applying the ClonTracer barcoding system, we were able to show the presence of pre-existing sub-populations in HCC827 that contribute to erlotinib resistance. Prior studies implicated that MET amplification confers resistance to erlotinib in this cell line. Therefore we examined the effects of the c-Met inhibitor crizotinib on the barcoded HCC827 population when treated either sequentially or simultaneously with both inhibitors. Despite the significant reduction in barcode complexity, the erlotinib/crizotinib combination treatment failed to eradicate all of the resistant clones implying the presence of an erlotinib/crizotinib dual resistant subpopulation. We performed transcriptome profiling (RNA-seq) to elucidate the potential resistance mechanisms of the dual resistant subpopulation in comparison to vehicle-treated or single agent erlotinib-resistant HCC827 cell populations as controls.

2014-10-07 | GSE62118 | GEO

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

2014-10-07 | E-GEOD-62118 | biostudies-arrayexpress

Differential Gene Expression in Erlotinib-Treated Fibroblasts

Project description:Analysis of human, adult, dermal fibroblasts following treatment with 100nM or 1 uM of erlotinib, a tryrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) inhibiting EGFR activation and signaling. Erlotinib is widely used to effectively treat patients with advanced non-small cell lung cancer but treatment with erlotinib and other EGFR TKIs are associated with a painful skin rash. Results identified significantly differentially expressed genes in fibroblasts treated with erlotinib providing insight into how the drug alters the transcriptome in ways that may contribute to the TKI-related rash.

2019-01-01 | GSE106151 | GEO

Impact of Erlotinib incubation on primary human keratinocytes and fibroblasts

Project description:We used next generation sequencing to analyze the effects of Erlotinib incubation on primary human keratinozytes and fibroblasts. We compared miRNA expression in cell lines more reactive to Erlotinib against cell lines less reactive to Erlotinib

2021-04-30 | GSE159602 | GEO

gene expression profiles in PC9 erlotinib resistance cells after erlotinib, HDAC inhibitor YF454A or combination treatment

Project description:To identify the potential mechanisms of enhanced activity of combined inhibition of erlotinib and YF454A, we conducted a microarray analysis on gene expression profiles in PC9 erlotinib cells. We used Affymetrix GeneChip® Human Transcriptome Array 2.0 to detail gene expression after indicated treatments and identified the molecular mechanism during this process to facilitate further studies.

2016-04-16 | GSE80316 | GEO

RNA deep sequencing analysis of glioma stem cells(GSCs) and non-GSCs

Project description:RNA deep sequencing analysis of glioma stem cells(GSCs) and non-GSCs

| PRJNA423102 | ENA

Gene expression profiling of Glioma Stem Cells (GSCs) and their differentiated cell counterparts after MG132 treatment

Project description:Analysis of genes in GSCs and differentiated cells that are induced by MG132 treatment.

2014-10-15 | GSE62356 | GEO

Gene expression profiling of generated Erlotinib-resistant (ER) cell lines

Project description:Targeted therapies have provided advantages to cancer patients, but these therapies are limited by differential responses and developed resistance. To discover mechanisms of resistance, we developed drug-resistant cell lines and have their gene expressions profiled and compared. HCC827 cells, which were initially sensitive to Erlotinib treatment, are subjected to Erlotinib treatment. Two clonal populations that resistant to Erlotinib resulted.

2012-06-15 | E-GEOD-38121 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data